Establishment Labs Holdings (ESTA) drew investor attention on 6 August 2026 after reporting second quarter results with higher sales, a smaller net loss than a year earlier, and raised full year revenue guidance.
See our latest analysis for Establishment Labs Holdings.
Despite the earnings beat and raised guidance on 6 August 2026, Establishment Labs Holdings shares closed at US$91.25 after a 1 day share price return that declined 3.55%. However, the 90 day share price return of 26.68% and 1 year total shareholder return of 118.35% suggest momentum has built over a longer stretch.
If you are looking for other potential ideas in healthcare and medical technology, this could be a good time to scan the market using our screener of 42 healthcare AI stocks
After Establishment Labs Holdings rallied over the past year yet slipped on the latest results, the real issue is timing. Does the current price already reflect the stronger guidance, or is patience on a better entry point more sensible before weighing valuation?
Most Popular Narrative: 4.3% Undervalued
Compared with the most followed narrative fair value of $95.33, Establishment Labs Holdings at $91.25 is priced slightly below that central estimate.
Accelerating surgeon adoption and utilization curve in the U.S., combined with further account additions and growing patient demand (amplified by patient-driven requests and social media engagement), positions the company for continued strong revenue growth and sustainable market share gains in a large, culturally receptive, and increasingly affluent market.
Want to know what kind of revenue ramp and margin shift would support that valuation gap closing? The narrative builds around rapid top line compounding, a step change in profitability, and a future earnings multiple that sits well above broader medtech. Curious which specific milestones need to fall into place for that story to hold up?
Result: Fair Value of $95.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Establishment Labs Holdings still faces real pressure points, including high SG&A and R&D spending, as well as heavy reliance on its Motiva implant portfolio.
Find out about the key risks to this Establishment Labs Holdings narrative.
Another View on Establishment Labs Holdings Valuation
The fair value narrative pegs Establishment Labs Holdings at $95.33, which suggests the current $91.25 price sits modestly below that point. Yet on a P/S basis the stock trades at 11.7x, compared with an industry average of 2.9x and a fair ratio of 6x, which implies a rich premium that could matter if sentiment cools.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mix of optimism and concern around Establishment Labs Holdings leaves you undecided, take a closer look at the underlying data and form your own view quickly. Then, to understand what the market is cheering, review the 1 key reward
Looking for more investment ideas beyond Establishment Labs Holdings?
Do not stop with Establishment Labs Holdings. Use the Simply Wall St screener to spot other opportunities that match your goals before the market moves on.
- Target stronger balance sheets and steadier fundamentals by scanning the solid balance sheet and fundamentals stocks screener (50 results) that can handle tough conditions and still stay resilient.
- Hunt for quality at sensible prices using the 51 high quality undervalued stocks that highlights companies with fundamentals that may not be fully reflected in their share prices.
- Prioritise stability and lower risk profiles with the 79 resilient stocks with low risk scores so you are not chasing returns without understanding potential downside.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com